135 related articles for article (PubMed ID: 23357500)
21. Mesonephric-like adenocarcinoma harbours characteristic copy number variations and a distinct DNA methylation signature closely related to mesonephric adenocarcinoma of the cervix.
Kommoss FK; Lee CH; Tessier-Cloutier B; Gilks CB; Stewart CJ; von Deimling A; Köbel M
J Pathol; 2024 Jan; 262(1):4-9. PubMed ID: 37850576
[TBL] [Abstract][Full Text] [Related]
22. Expression and clinical significance of Ki-67, E-cadherin, and mesothelin in serous borderline ovarian tumor.
Yu N; Wang N; Liu YF; Li YY; Zhang TG
Eur J Gynaecol Oncol; 2017; 38(1):85-90. PubMed ID: 29767871
[TBL] [Abstract][Full Text] [Related]
23. [Serous ovarian tumors].
Diebold J
Pathologe; 2014 Jul; 35(4):314-21. PubMed ID: 24916775
[TBL] [Abstract][Full Text] [Related]
24. DNA Methylome Analyses Implicate Fallopian Tube Epithelia as the Origin for High-Grade Serous Ovarian Cancer.
Klinkebiel D; Zhang W; Akers SN; Odunsi K; Karpf AR
Mol Cancer Res; 2016 Sep; 14(9):787-94. PubMed ID: 27259716
[TBL] [Abstract][Full Text] [Related]
25. Serous and mucinous borderline (low malignant potential) tumors of the ovary.
Acs G
Am J Clin Pathol; 2005 Jun; 123 Suppl():S13-57. PubMed ID: 16100867
[TBL] [Abstract][Full Text] [Related]
26. Low-grade Serous Carcinoma of the Ovary: Clinicopathologic Analysis of 52 Invasive Cases and Identification of a Possible Noninvasive Intermediate Lesion.
Ahn G; Folkins AK; McKenney JK; Longacre TA
Am J Surg Pathol; 2016 Sep; 40(9):1165-76. PubMed ID: 27487741
[TBL] [Abstract][Full Text] [Related]
27. A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer.
Lo Riso P; Villa CE; Gasparoni G; Vingiani A; Luongo R; Manfredi A; Jungmann A; Bertolotti A; Borgo F; Garbi A; Lupia M; Laise P; Das V; Pruneri G; Viale G; Colombo N; Manzo T; Nezi L; Cavallaro U; Cacchiarelli D; Walter J; Testa G
Genome Med; 2020 Oct; 12(1):94. PubMed ID: 33121525
[TBL] [Abstract][Full Text] [Related]
28. A rat model of serous borderline ovarian tumors induced by 7,12-dimethylbenz[a]anthracene.
Cai SQ; Li Y; Li YA; Wang L; Zhu J; Zhao SH; Li X; Qiang JW
Exp Anim; 2019 Aug; 68(3):257-265. PubMed ID: 30760660
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of p53 induces invasion of serous borderline ovarian tumor cells by accentuating PI3K/Akt-mediated suppression of E-cadherin.
Cheng JC; Auersperg N; Leung PC
Oncogene; 2011 Mar; 30(9):1020-31. PubMed ID: 20972462
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.
Chui MH; Xing D; Zeppernick F; Wang ZQ; Hannibal CG; Frederiksen K; Kjaer SK; Cope L; Kurman RJ; Shih IM; Wang TL; Vang R
Am J Surg Pathol; 2019 Nov; 43(11):1462-1472. PubMed ID: 31343420
[TBL] [Abstract][Full Text] [Related]
31. Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas.
Staebler A; Heselmeyer-Haddad K; Bell K; Riopel M; Perlman E; Ried T; Kurman RJ
Hum Pathol; 2002 Jan; 33(1):47-59. PubMed ID: 11823973
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of MTAP immunohistochemistry loss of expression in ovarian serous borderline tumors as a potential marker for prognosis and progression.
Nilforoushan N; Moatamed NA
Ann Diagn Pathol; 2020 Oct; 48():151582. PubMed ID: 32866902
[TBL] [Abstract][Full Text] [Related]
33. Rare metastatic patterns after malignant transformation of serous borderline tumor of the ovary.
Siemon J; Nguyen DM; Pinto A; Schlumbrecht M
J Surg Oncol; 2019 May; 119(6):814-816. PubMed ID: 30648273
[TBL] [Abstract][Full Text] [Related]
34. Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary.
May T; Virtanen C; Sharma M; Milea A; Begley H; Rosen B; Murphy KJ; Brown TJ; Shaw PA
Gynecol Oncol; 2010 Apr; 117(1):9-17. PubMed ID: 20117829
[TBL] [Abstract][Full Text] [Related]
35. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
Dehari R; Kurman RJ; Logani S; Shih IeM
Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
[TBL] [Abstract][Full Text] [Related]
36. Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma.
Qiu C; Wang Y; Wang X; Zhang Q; Li Y; Xu Y; Jin C; Bu H; Zheng W; Yang X; Lu N; Kong B
Int J Oncol; 2018 Jun; 52(6):2041-2050. PubMed ID: 29620196
[TBL] [Abstract][Full Text] [Related]
37. Ovarian high-grade serous carcinoma with a noninvasive growth pattern simulating a serous borderline tumor.
Imamura H; Ohishi Y; Aman M; Shida K; Shinozaki T; Yasutake N; Sonoda K; Kato K; Oda Y
Hum Pathol; 2015 Oct; 46(10):1455-63. PubMed ID: 26232113
[TBL] [Abstract][Full Text] [Related]
38. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers.
Wei SH; Chen CM; Strathdee G; Harnsomburana J; Shyu CR; Rahmatpanah F; Shi H; Ng SW; Yan PS; Nephew KP; Brown R; Huang TH
Clin Cancer Res; 2002 Jul; 8(7):2246-52. PubMed ID: 12114427
[TBL] [Abstract][Full Text] [Related]
39. Genomic heterogeneity in peritoneal implants: A differential analysis of gene expression using nanostring Human Cancer Reference panel identifies a malignant signature.
Mhawech-Fauceglia P; Izevbaye I; Spindler T; Wang G; Hwang H; Samrao D; Elishaev E; Maxwell GL; Lawrenson K; Darcy KM
Gynecol Oncol; 2020 Jan; 156(1):6-12. PubMed ID: 31711656
[TBL] [Abstract][Full Text] [Related]
40. K-RAS mutations in ovarian and extraovarian lesions of serous tumors of borderline malignancy.
Diebold J; Seemüller F; Löhrs U
Lab Invest; 2003 Feb; 83(2):251-8. PubMed ID: 12594239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
